Collaborative Breakthrough in Lung Cancer Research by ICRF and The Mark Foundation
Groundbreaking Lung Cancer Research Initiative
In a significant move for lung cancer research, the Israel Cancer Research Fund (ICRF) has teamed up with The Mark Foundation for Cancer Research (MFCR) to support a pioneering project grant. This collaboration has resulted in the ICRF-Mark Foundation Collaborative Project Grant, awarded to prominent researcher Yosef Yarden, Ph.D., from the Weizmann Institute of Science in Israel.
Focus of the Research
The grant, amounting to $180,000 over three years, is aimed at developing antibody-based therapies specifically for EGFR-positive lung cancer. This form of lung cancer is notoriously aggressive and resistant to conventional treatments, posing serious challenges to patient survival.
Alan Herman, Executive Director of ICRF, expressed enthusiasm about this partnership, emphasizing the importance of investing in high-potential research that targets the urgent needs of patients suffering from this difficult condition. “By supporting Prof. Yarden's innovative antibody research, we are investing in bold ideas that could transform outcomes for patients with treatment-resistant lung cancer who urgently need better options,” Herman stated.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.